Tvardi Therapeutics
TVRD
181 hedge funds and large institutions have $369M invested in Tvardi Therapeutics in 2021 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 49 increasing their positions, 56 reducing their positions, and 24 closing their positions.
84% more call options, than puts
Call options by funds: $5.9M | Put options by funds: $3.2M
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
6% more funds holding
Funds holding: 170 → 181 (+11)
2.42% less ownership
Funds ownership: 59.09% → 56.67% (-2.4%)
13% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 56
19% less capital invested
Capital invested by funds: $457M → $369M (-$88.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.96M |
| 2 |
Renaissance Technologies
New York
|
+$5.04M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5M |
| 4 |
JP Morgan Chase
New York
|
+$3.06M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16M |
| 2 |
Jane Street
New York
|
-$2.73M |
| 3 |
Goldman Sachs
New York
|
-$2.53M |
| 4 |
Morgan Stanley
New York
|
-$1.33M |
| 5 |
Two Sigma Advisers
New York
|
-$1.05M |
TVRD Hedge Fund Activity: Q4 2021 in Review
181 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2021, worth a combined $369M — down 19% from $457M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new TVRD positions and 24 closed out — a net gain of 12 holders — while 49 added to existing stakes and 56 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $5.96M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16M sold.
- 181 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2021, up from 170 in Q3 2021.
- Funds reported $369M of Tvardi Therapeutics stock for Q4 2021, down 19% quarter-over-quarter.
- 36 funds opened new Tvardi Therapeutics positions in Q4 2021 and 24 closed out, a net change of +12 holders.
- The largest Tvardi Therapeutics buyer in Q4 2021 was Soleus Capital Management, an estimated $5.96M added.
- The largest Tvardi Therapeutics seller in Q4 2021 was T. Rowe Price Associates, an estimated $16M sold.
Based on aggregated 13F filings for Q4 2021.